Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Target spot for treating septicemia

A septicemia and target technology, applied in the field of septicemia treatment, can solve problems such as side effects and achieve the effect of improving living conditions

Inactive Publication Date: 2012-07-25
MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
View PDF1 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

We know that the stress state of the body is an "over" response of various systems in a critical state, which can temporarily protect the body from the current injury, but the side effects caused by this are also obvious, and even more serious.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Target spot for treating septicemia
  • Target spot for treating septicemia
  • Target spot for treating septicemia

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1. Confirmation and verification of Factor XI as a therapeutic target for sepsis

[0034] 1. Detection of mRNA gene chip after low-dose (sublethal) and high-dose (lethal) Listeria infection:

[0035] (1) Intraperitoneally injected Listeria monocytogenes (L.monocytogenes, EGD strain) into C57BL / 6 mice, passaged, isolated spleen, ground TSA and cultured, picked monoclonal TSB, cultured, counted, and stored in -70°C refrigerator for later use. The LD50 of this strain is 2×10 6 CFU. Dilute cryopreserved bacteria in PBS to the desired infectious dose, with a low dose of 0.6-1.0 x 10 5 CFU, high dose 2.5-2.7×10 6 CFU, the final injection volume was 200 μl.

[0036] (2) C57BL / 6 mice were raised in SPF (specific pathogen free) laboratory for 6-8 weeks, and the food, water and excipients were changed regularly. The 15 mice were divided into three groups and injected with 200 μl low and high doses of Listeria, respectively, and a 200 μl PBS blank control group was es...

Embodiment 2

[0057] Example 2. Discussion on the mechanism of Factor XI as a therapeutic target for sepsis

[0058] (1) Intraperitoneally injected Listeria monocytogenes (L.monocytogenes, EGD strain) into C57BL / 6 mice, passaged, isolated spleen, ground TSA and cultured, picked monoclonal TSB, cultured, counted, and stored in -70°C refrigerator for later use. The LD50 of this strain is 2×10 6 CFU. Use PBS to dilute the cryopreserved bacteria to the required infectious dose, the final injection volume is 200 μl, the so-called low dose in this example is 0.6-1.0 × 10 5 CFU, high dose is 2.5-2.7×10 6 CFU;

[0059] (2) Factor XI HET mice were mated and screened to 6-8 weeks. There were 5 strict control mice in each group, namely Factor XI WT, Factor XIHET, and Factor XI KO. They were raised in an SPF (specific pathogen free) laboratory, and their food was changed regularly. , water and excipients. 200 μl of low-dose and high-dose Listeria were injected respectively, and a 200 μl PBS blank ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a target spot for treating septicemia, belonging to the technical field of treatment of septicemia. The target spot is Factor XI or Factor XII, and can block a Factor XI or Factor XII expression in a septicemia patient body so as to treat septicemia. According to the invention, an antibody-14E11for blocking the Factor XI expression is a novel medicine for treating septicemia after the APC (aspirin compound tablet), and due to the special position of Factor XI on a clotting cascade chain, the occurrence rate of side effects should be obviously lower than that of the APC.

Description

technical field [0001] The invention belongs to the technical field of septicemia treatment, and in particular relates to a target for septicemia treatment. Background technique [0002] Sepsis (septicemia) refers to the acute systemic infection caused by pathogenic bacteria or opportunistic pathogenic bacteria invading the blood circulation, growing and multiplying in the blood, and producing toxins. If the bacteria invading the bloodstream are cleared by the body's defense function and there is no obvious symptom of toxemia, it is called bacteremia (bacteriemia). Septicemia with multiple abscesses and a longer course of disease is called pyemia. . The clinical manifestations of patients vary with the type, quantity, virulence, age and resistance of the pathogenic bacteria. In mild cases, there are only general symptoms of infection, while in severe cases, septic shock, DIC (disseminated intravascular coagulation), and MODS (multiple organs dysfunction syndrome) may occur...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61K48/00A61P31/04
Inventor 罗德炎
Owner MICROBE EPIDEMIC DISEASE INST OF PLA MILITARY MEDICAL ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products